Modular Medical regains Nasdaq listing compliance
Modular Medical, Inc. has regained compliance with the Nasdaq Capital Market’s minimum bid price continued listing requirement.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Modular Medical, Inc. has regained compliance with the Nasdaq Capital Market’s minimum bid price continued listing requirement. Nasdaq notified the company after its common stock maintained a closing bid above the $1.00 minimum for 10 consecutive trading days through April 14, 2026.
With compliance restored under Nasdaq Listing Rule 5550(a)(2), Nasdaq considers the matter closed, meaning the company’s common stock can continue trading on the Nasdaq Capital Market under the symbol MODD without an active bid-price deficiency issue.
Positive
- Regained Nasdaq compliance: The company once again meets the Nasdaq Capital Market’s minimum bid price requirement, removing an immediate delisting overhang and helping preserve trading liquidity and market visibility.
Negative
- None.
Insights
Regaining Nasdaq bid-price compliance removes an immediate delisting risk for Modular Medical.
Modular Medical confirmed that its stock traded above the $1.00 minimum bid for 10 straight sessions as of April 14, 2026, restoring compliance with Nasdaq Listing Rule 5550(a)(2). Nasdaq has closed the deficiency matter.
This outcome is important because continued Nasdaq listing supports liquidity, visibility, and index eligibility. Losing that listing can constrain access to capital and deter some institutional investors. While no new financial results are disclosed, the resolution of a potential delisting overhang is a clearly favorable development.
Future filings may clarify how the company plans to leverage its maintained listing status as it advances its development-stage insulin delivery technology, but this notice itself simply confirms the company now meets Nasdaq’s bid-price standard.
8-K Event Classification
Key Figures
Key Terms
minimum bid price requirement financial
Nasdaq Capital Market financial
Nasdaq Listing Rule 5550(a)(2) regulatory
development-stage medical device company financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Modular Medical (MODD) announce in this 8-K filing?
What is the Nasdaq minimum bid price requirement affecting MODD?
When did Modular Medical regain compliance with Nasdaq rules?
Does this Nasdaq compliance notice change Modular Medical’s listing status?
What business is Modular Medical (MODD) focused on?
Why is maintaining Nasdaq listing important for Modular Medical investors?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported):
(Exact Name of Registrant as Specified in Charter)
(Commission File Number)
| (State or Other Jurisdiction of Incorporation) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices, with zip code)
(
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On April 16, 2026, Modular Medical, Inc. (the “Company”) issued a press release announcing the Company received a notification letter on April 15, 2026 from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that it had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). A copy of the press release is filed as Exhibit 99.1 to this Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 | Press Release by Modular Medical, Inc. dated April 16, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MODULAR MEDICAL, INC. | ||
| Date: April 16, 2026 | By: | /s/ James Besser |
| James Besser | ||
| Chief Executive Officer | ||
2
Exhibit 99.1
Modular Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO, CA / ACCESSWIRE / April 16, 2026 / Modular Medical, Inc. (“Modular Medical” or the “Company”) (NASDAQ: MODD), a leader in innovative, patient-centric insulin delivery, today announced that it has received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the Nasdaq Capital Market’s minimum bid price continued listing requirement. The letter noted that, as of April 14, 2026, the Company evidenced a closing bid price of its common stock in excess of the $1.00 minimum requirement for the last 10 consecutive trading days. Accordingly, the Company has regained compliance with Nasdaq Marketplace Rule 5550(a)(2) and Nasdaq considers the matter closed.
About Modular Medical
Modular Medical, Inc. (Nasdaq: MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond “superusers” and providing “diabetes care for the rest of us.”
Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.
CONTACT:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com